KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2026)

Amneal Pharmaceuticals has reported Restructuring Costs over the past 9 years, most recently at $2.5 million for Q4 2025.

  • For Q4 2025, Restructuring Costs rose 401.01% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $4.2 million, up 78.68%, while the annual FY2025 figure was $4.2 million, 78.68% up from the prior year.
  • Restructuring Costs for Q4 2025 was $2.5 million at Amneal Pharmaceuticals, up from $143000.0 in the prior quarter.
  • Over five years, Restructuring Costs peaked at $2.5 million in Q4 2025 and troughed at -$612000.0 in Q4 2022.
  • A 5-year average of $603833.3 and a median of $501500.0 in 2023 define the central range for Restructuring Costs.
  • Biggest five-year swings in Restructuring Costs: crashed 157.25% in 2022 and later soared 401.01% in 2025.
  • Year by year, Restructuring Costs stood at $1.1 million in 2021, then crashed by 157.25% to -$612000.0 in 2022, then surged by 118.63% to $114000.0 in 2023, then soared by 332.46% to $493000.0 in 2024, then soared by 401.01% to $2.5 million in 2025.
  • Business Quant data shows Restructuring Costs for AMRX at $2.5 million in Q4 2025, $143000.0 in Q3 2025, and $1.0 million in Q2 2025.